Mutant Mice Lacking the p53 C-Terminal Domain Model Telomere Syndromes

Cell Reports

Volumn 3, Issue 6, 2013, Pages 2046-2058

  Simeonova, Iva ^a,b,c   Jaber, Sara ^a,b,c   Draskovic, Irena ^a,b,c   Bardot, Boris ^a,b,c   Fang, Ming ^a,b,c   Bouarich Bourimi, Rachida ^a,b,c   Lejour, Vincent ^a,b,c   Charbonnier, Laure ^a,b,c   Soudais, Claire ^a,d   Bourdon, Jean Christophe ^e   Huerre, Michel ^a   Londono Vallejo, Arturo ^a,b,c   Toledo, Franck ^a,b,c  

^a INSTITUT CURIE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institut Curie   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; PROTEIN MDMX; PROTEIN P53; TELOMERIC REPEAT BINDING FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APLASTIC ANEMIA; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DYSKERATOSIS CONGENITA; DYSKERIN GENE; GENE; GENE LOCUS; GENETIC DISORDER; HETEROZYGOSITY; HUMAN; HUMAN CELL; LUNG FIBROSIS; METABOLIC REGULATION; MOUSE; MOUSE MUTANT; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RTEL1 GENE; TELOMERE; TELOMERE SHORTENING; TELOMERIC REPEAT BINDING FACTOR 1 GENE; TINF2 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; MUTATION; PROTEIN STRUCTURE, TERTIARY; SYNDROME; TELOMERE; TELOMERE-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84879794532     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.05.028     Document Type: Article

References (53)

1. Arai N., Nomura D., Yokota K., Wolf D., Brill E., Shohat O., Rotter V. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 1986, 6:3232-3239.
2. Armanios M., Blackburn E.H. The telomere syndromes. Nat. Rev. Genet. 2012, 13:693-704.
3. Baerlocher G.M., Vulto I., de Jong G., Lansdorp P.M. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat. Protoc. 2006, 1:2365-2376.
4. Ballew B.J., Yeager M., Jacobs K., Giri N., Boland J., Burdett L., Alter B.P., Savage S.A. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Hum. Genet. 2013, 132:473-480.
5. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
6. Brady C.A., Attardi L.D. p53 at a glance. J.Cell Sci. 2010, 123:2527-2532.
7. Bruins W., Zwart E., Attardi L.D., Iwakuma T., Hoogervorst E.M., Beems R.B., Miranda B., van Oostrom C.T., van den Berg J., van den Aardweg G.J., et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol. Cell. Biol. 2004, 24:8884-8894.
8. Ding H., Schertzer M., Wu X., Gertsenstein M., Selig S., Kammori M., Pourvali R., Poon S., Vulto I., Chavez E., et al. Regulation of murine telomere length by Rtel: an essential gene encoding a helicase-like protein. Cell 2004, 117:873-886.
9. Dumble M., Moore L., Chambers S.M., Geiger H., Van Zant G., Goodell M.A., Donehower L.A. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 2007, 109:1736-1742.
10. Espinosa J.M. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 2008, 27:4013-4023.
11. Feng L., Lin T., Uranishi H., Gu W., Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 2005, 25:5389-5395.
12. Foord O.S., Bhattacharya P., Reich Z., Rotter V. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res. 1991, 19:5191-5198.
13. Fujita K., Horikawa I., Mondal A.M., Jenkins L.M., Appella E., Vojtesek B., Bourdon J.C., Lane D.P., Harris C.C. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat. Cell Biol. 2010, 12:1205-1212.
14. Hamard P.J., Lukin D.J., Manfredi J.J. p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes. J.Biol. Chem. 2012, 287:22397-22407.
15. He H., Wang Y., Guo X., Ramchandani S., Ma J., Shen M.F., Garcia D.A., Deng Y., Multani A.S., You M.J., Chang S. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol. Cell. Biol. 2009, 29:229-240.
16. Herrera-Merchan A., Cerrato C., Luengo G., Dominguez O., Piris M.A., Serrano M., Gonzalez S. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010, 9:3277-3285.
17. Hockemeyer D., Palm W., Wang R.C., Couto S.S., de Lange T. Engineered telomere degradation models dyskeratosis congenita. Genes Dev. 2008, 22:1773-1785.
18. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell 1992, 71:875-886.
19. Kaeser M.D., Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity invivo. Proc. Natl. Acad. Sci. USA 2002, 99:95-100.
20. Kim H., Kim K., Choi J., Heo K., Baek H.J., Roeder R.G., An W. p53 requires an intact C-terminal domain for DNA binding and transactivation. J.Mol. Biol. 2012, 415:843-854.
21. Krummel K.A., Lee C.J., Toledo F., Wahl G.M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 2005, 102:10188-10193.
22. Lane D., Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2010, 2:a000893.
23. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
24. Liu G., Terzian T., Xiong S., Van Pelt C.S., Audiffred A., Box N.F., Lozano G. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J.Pathol. 2007, 213:360-368.
25. Liu D., Ou L., Clemenson G.D., Chao C., Lutske M.E., Zambetti G.P., Gage F.H., Xu Y. Puma is required for p53-induced depletion of adult stem cells. Nat. Cell Biol. 2010, 12:993-998.
26. Löhr K., Möritz C., Contente A., Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J.Biol. Chem. 2003, 278:32507-32516.
27. Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
28. McGowan K.A., Li J.Z., Park C.Y., Beaudry V., Tabor H.K., Sabnis A.J., Zhang W., Fuchs H., de Angelis M.H., Myers R.M., et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat. Genet. 2008, 40:963-970.
29. McKinney K., Mattia M., Gottifredi V., Prives C. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 2004, 16:413-424.
30. Mendrysa S.M., McElwee M.K., Michalowski J., O'Leary K.A., Young K.M., Perry M.E. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 2003, 23:462-472.
31. Meyer K.D., Lin S.C., Bernecky C., Gao Y., Taatjes D.J. p53 activates transcription by directing structural shifts in Mediator. Nat. Struct. Mol. Biol. 2010, 17:753-760.
32. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.
33. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
34. Ourliac-Garnier I., Londoño-Vallejo A. Telomere strand-specific length analysis by fluorescent insitu hybridization (Q-CO-FISH). Methods Mol. Biol. 2011, 735:33-46.
35. Parry E.M., Alder J.K., Lee S.S., Phillips J.A., Loyd J.E., Duggal P., Armanios M. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J.Med. Genet. 2011, 48:327-333.
36. Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 2011, 117:5607-5611.
37. Pereboom T.C., van Weele L.J., Bondt A., MacInnes A.W. A zebrafish model of dyskeratosis congenita reveals hematopoietic stem cell formation failure resulting from ribosomal protein-mediated p53 stabilization. Blood 2011, 118:5458-5465.
38. Poyurovsky M.V., Katz C., Laptenko O., Beckerman R., Lokshin M., Ahn J., Byeon I.J., Gabizon R., Mattia M., Zupnick A., et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat. Struct. Mol. Biol. 2010, 17:982-989.
39. Prophet E., Mills B., Arrington J., Sobin L. Laboratory Methods in Histotechnology 1992, AFIP, Washington, DC.
40. Simeonova I., Lejour V., Bardot B., Bouarich-Bourimi R., Morin A., Fang M., Charbonnier L., Toledo F. Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes. PLoS Genet. 2012, 8:e1002731.
41. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., Chang E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990, 348:747-749.
42. Tafvizi A., Huang F., Fersht A.R., Mirny L.A., van Oijen A.M. A single-molecule characterization of p53 search on DNA. Proc. Natl. Acad. Sci. USA 2011, 108:563-568.
43. Takenaka I., Morin F., Seizinger B.R., Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J.Biol. Chem. 1995, 270:5405-5411.
44. Terzian T., Wang Y., Van Pelt C.S., Box N.F., Travis E.L., Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol. Cell. Biol. 2007, 27:5479-5485.
45. Toledo F., Wahl G.M. Regulating the p53 pathway: invitro hypotheses, invivo veritas. Nat. Rev. Cancer 2006, 6:909-923.
46. Toledo F., Krummel K.A., Lee C.J., Liu C.W., Rodewald L.W., Tang M., Wahl G.M. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006, 9:273-285.
47. Toledo F., Liu C.W., Lee C.J., Wahl G.M. RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res. 2006, 34:e92.
48. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression invivo. Nature 2007, 445:661-665.
49. Vulliamy T.J., Kirwan M.J., Beswick R., Hossain U., Baqai C., Ratcliffe A., Marsh J., Walne A., Dokal I. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations. PLoS One 2011, 6:e24383.
50. Walne A.J., Vulliamy T., Kirwan M., Plagnol V., Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am. J. Hum. Genet. 2013, 92:448-453.
51. Wang Y.V., Leblanc M., Fox N., Mao J.H., Tinkum K.L., Krummel K., Engle D., Piwnica-Worms D., Piwnica-Worms H., Balmain A., et al. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev. 2011, 25:1426-1438.
52. Wang Y., Shen M.F., Chang S. Essential roles for Pot1b in HSC self-renewal and survival. Blood 2011, 118:6068-6077.
53. Zhong F., Savage S.A., Shkreli M., Giri N., Jessop L., Myers T., Chen R., Alter B.P., Artandi S.E. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev. 2011, 25:11-16.